LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1

C.A. Kristensen, Robert L. Metcalf, I. Braña, Simon Laban, Ainara Soria Rivas, D. Grose, J. Rubio Casadevall, V. Cheshuk, Sebastian M. Dieter, A. Lopez Pousa, Stefan Kasper‐Virchow, B. Doger de Spéville, M. Covela, Florian D. Vogl, C. Mueller, Frédéric Triebel